MYGN Myriad Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MYGN

Price (delayed)

$5.99

Market cap

$565.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.29

Enterprise value

$652.84M

?
Relative Growth: Rel. Growth: 7
Relative Strength: Rel. Strength: 46
Relative Valuation: Rel. Valuation: 34
Relative Profitability: Rel. Profitability: 15

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
The quick ratio has increased by 36% year-on-year but it has declined by 3.5% since the previous quarter
The company's equity has shrunk by 52% YoY and by 8% QoQ
The debt has grown by 34% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.myriad.com/
Peers: BMRN BIO ABT

Key stats

What are the main financial stats of MYGN

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
-0.17%
1 week
10.31%
1 month
38.98%
1 year
6.39%
YTD
-2.6%
QTD
4.9%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$829M
Gross profit
$580M
Operating income
-$388.9M
Net income
-$399.9M
Gross margin
70%
Net margin
-48.2%
The company's net income fell by 9% QoQ
The net margin has contracted by 9% from the previous quarter

Price vs fundamentals

How does MYGN's price correlate with its fundamentals

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
1.66
P/S
0.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.79
The EPS has contracted by 9% from the previous quarter
The company's equity has shrunk by 52% YoY and by 8% QoQ
MYGN's price to book (P/B) is 17% lower than its 5-year quarterly average of 2.0 but 11% higher than its last 4 quarters average of 1.5
The P/S is 66% lower than the 5-year quarterly average of 2.0 and 2.9% lower than the last 4 quarters average of 0.7

Efficiency

How efficient is Myriad Genetics business performance
The return on invested capital has dropped by 183% year-on-year but it has grown by 3.4% since the previous quarter
MYGN's return on equity is down by 37% since the previous quarter
Myriad Genetics's return on assets has decreased by 22% QoQ

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
Myriad Genetics's total assets is 100% more than its total liabilities
The quick ratio has increased by 36% year-on-year but it has declined by 3.5% since the previous quarter
Myriad Genetics's total assets has decreased by 33% YoY and by 4.7% from the previous quarter
The debt is 37% less than the equity
The debt to equity has soared by 186% year-on-year and by 11% since the previous quarter
The company's equity has shrunk by 52% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.